Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 458

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Silencing of Epidermal Growth Factor Receptor Suppresses Hypoxia-Inducible Factor-2–Driven VHL −/− Renal Cancer

Open access
Smith, Karlene, Gunaratnam, Lakshman, Morley, Melissa, Franovic, Aleksandra, Mekhail, Karim, Lee, Stephen·2005·Cancer Research
DOI 10.1158/0008-5472.can-05-0169

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Inactivating mutations in the von Hippel-Lindau (VHL) tumor suppressor gene are associated with clear cell renal cell carcinoma (VHL−/− RCC), the most frequent malignancy of the human kidney. The VHL protein targets the α subunits of hypoxia-inducible factor (HIF) transcription factor for ubiquitination and degradation. VHL−/− RCC cells fail to degrade HIF resulting in the constitutive activation of its target genes, a process that is required for tumorigenesis. We recently reported that HIF activates the transforming growth factor-α/epidermal growth factor receptor (TGF-α/EGFR) pathway in VHL-defective RCC cells. Here, we show that short hairpin RNA (shRNA)–mediated inhibition of EGFR is sufficient to abolish HIF-dependent tumorigenesis in multiple VHL−/− RCC cell lines. The 2α form of HIF (HIF-2α), but not HIF-1α, drives in vitro and in vivo tumorigenesis of VHL−/− RCC cells by specifically activating the TGF-α/EGFR pathway. Transient incubation of VHL−/− RCC cell lines with small interfering RNA directed against EGFR prevents autonomous growth in two-dimensional culture as well as the ability of these cells to form dense spheroids in a three-dimensional in vitro tumor assay. Stable expression of shRNA against EGFR does not alter characteristics associated with VHL loss including constitutive production of HIF targets and defects in fibronectin deposition. In spite of this, silencing of EGFR efficiently abolishes in vivo tumor growth of VHL loss RCC cells. These data identify EGFR as a critical determinant of HIF-2α-dependent tumorigenesis and show at the molecular level that EGFR remains a credible target for therapeutic strategies against VHL−/− renal carcinoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-05-0169

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 34

  1. Bukowski RM, Novick AC. Renal cell carcinoma: molecular biology, immunology, and clinical management. 1st ed. New Jersey: Humana Press Inc.; 2000.
  2. Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1995; 1: 822–6. · DOI · Paper page
  3. Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ, Maher ER. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1α in renal cell carcinoma. Oncogene 2001; 20: 5067–74. · DOI
  4. Iwai K, Yamanaka K, Kamura T, et al. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A 1999; 96: 12436–41. · DOI · Paper page
  5. Kamura T, Koepp DM, Conrad MN, et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999; 284: 657–61. · DOI · Paper page
  6. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001; 13: 167–71. · DOI · Paper page
  7. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107: 43–54. · DOI · Paper page
  8. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294: 1337–40. · DOI · Paper page
  9. Ohh M, Yauch RL, Lonergan KM, et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998; 1: 959–68. · DOI · Paper page
  10. Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG Jr, Ohh M. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol 2004; 24: 3251–61. · DOI · Paper page
  11. Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon MC. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Cancer Res 2004; 64: 8595–603. · DOI
  12. Sowter HM, Raval R, Moore J, Ratcliffe PJ, Harris AL. Predominant role of hypoxia-inducible transcription factor (Hif)-1α versus Hif-2α in regulation of the transcriptional response to hypoxia. Cancer Res 2003; 63: 6130–4.
  13. Seagroves T, Johnson RS. Two HIFs may be better than one. Cancer Cell 2002; 1: 211–3. · DOI
  14. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002; 1: 247–55. · DOI · Paper page
  15. Gunaratnam L, Morley M, Franovic A, et al. Hypoxia inducible factor activates the transforming growth factor-α/epidermal growth factor receptor growth stimulatory pathway in VHL(−/−) renal cell carcinoma cells. J Biol Chem 2003; 278: 44966–74. · DOI · Paper page
  16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70. · DOI · Paper page
  17. de Paulsen N, Brychzy A, Fournier MC, et al. Role of transforming growth factor-α in von Hippel-Lindau (VHL)(−/−) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A 2001; 98: 1387–92. · DOI
  18. Groulx I, Lee S. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol 2002; 22: 5319–36. · DOI · Paper page
  19. Bonicalzi ME, Groulx I, de Paulsen N, Lee S. Role of exon 2-encoded β-domain of the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2001; 276: 1407–16. · DOI
  20. Nagy P, Arndt-Jovin DJ, Jovin TM. Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells. Exp Cell Res 2003; 285: 39–49. · DOI
  21. Kunz-Schughart LA, Kreutz M, Knuechel R. Multicellular spheroids: a three-dimensional in vitro culture system to study tumour biology. Int J Exp Pathol 1998; 79: 1–23. · DOI · Paper page
  22. Lieubeau-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel RS. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 1998; 58: 4957–62.
  23. Mekhail K, Gunaratnam L, Bonicalzi ME, Lee S. HIF activation by pH-dependent nucleolar sequestration of VHL. Nat Cell Biol 2004; 6: 642–7. · DOI · Paper page
  24. Pause A, Lee S, Lonergan KM, Klausner RD. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A 1998; 95: 993–8. · DOI · Paper page
  25. Mandriota SJ, Turner KJ, Davies DR, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002; 1: 459–68. · DOI · Paper page
  26. Everitt JI, Walker CL, Goldsworthy TW, Wolf DC. Altered expression of transforming growth factor-α: an early event in renal cell carcinoma development. Mol Carcinog 1997; 19: 213–9. · doi:10.1002/(sici)1098-2744(199707)19:3<213::aid-mc9>3.0.co;2-e
  27. Gomella LG, Sargent ER, Wade TP, Anglard P, Linehan WM, Kasid A. Expression of transforming growth factor α in normal human adult kidney and enhanced expression of transforming growth factors α and β 1 in renal cell carcinoma. Cancer Res 1989; 49: 6972–5. · doi:10.3727/095535489820874904
  28. Knebelmann B, Ananth S, Cohen HT, Sukhatme VP. Transforming growth factor α is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 1998; 58: 226–31.
  29. Koochekpour S, Jeffers M, Wang PH, et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999; 19: 5902–12. · DOI · Paper page
  30. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411–21. · DOI · Paper page
  31. Ratcliffe PJ, Pugh CW, Maxwell PH. Targeting tumors through the HIF system. Nat Med 2000; 6: 1315–6. · DOI
  32. Weber KL, Doucet M, Price JE, Baker C, Kim SJ, Fidler IJ. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 2003; 63: 2940–7.
  33. Dancey JE. Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: do we need a better mouse trap? J Clin Oncol 2004; 22: 2975–7. · DOI
  34. Drucker B, Bacik J, Ginsberg M, et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 2003; 21: 341–5. · doi:10.1023/a:1025472712456

Cited by

See all 458

Metadata

Authors
Smith, K., Gunaratnam, L., Morley, M., Franovic, A., Mekhail, K., & Lee, S.
Venue
Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2005-06-15
Volume
65
Issue
12
Pages
5221-5230
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
DOI
10.1158/0008-5472.can-05-0169
OpenAlex
W2151856174
Cited by
458
References
16
FWCI
11.31
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Silencing of Epidermal Growth Factor Receptor Suppresses Hypoxia-Inducible Factor-2–Driven VHL −/− Renal Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-0169
The paper
Smith, K., Gunaratnam, L., Morley, M., Franovic, A., Mekhail, K., & Lee, S. (2005). Silencing of Epidermal Growth Factor Receptor Suppresses Hypoxia-Inducible Factor-2–Driven VHL −/− Renal Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-0169

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.